CY1109996T1 - Ανοσογονικη συνθεση - Google Patents

Ανοσογονικη συνθεση

Info

Publication number
CY1109996T1
CY1109996T1 CY20101100387T CY101100387T CY1109996T1 CY 1109996 T1 CY1109996 T1 CY 1109996T1 CY 20101100387 T CY20101100387 T CY 20101100387T CY 101100387 T CY101100387 T CY 101100387T CY 1109996 T1 CY1109996 T1 CY 1109996T1
Authority
CY
Cyprus
Prior art keywords
saccharide
immune composition
hib
conjugate
dose
Prior art date
Application number
CY20101100387T
Other languages
Greek (el)
English (en)
Inventor
Ralph Leon Biemans
Jan Poolman
Pierre Duvivier
Philippe Denoel
Carine Capiau
Dominique Boutriau
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109996(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1109996T1 publication Critical patent/CY1109996T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)
CY20101100387T 2005-06-27 2010-04-30 Ανοσογονικη συνθεση CY1109996T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
EP06754596A EP1896062B1 (en) 2005-06-27 2006-06-23 Immunogenic composition

Publications (1)

Publication Number Publication Date
CY1109996T1 true CY1109996T1 (el) 2014-09-10

Family

ID=36716943

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20101100387T CY1109996T1 (el) 2005-06-27 2010-04-30 Ανοσογονικη συνθεση
CY20111100883T CY1111827T1 (el) 2005-06-27 2011-09-15 Μεθοδος βιομηχανικης κατασκευης εμβολιων
CY20121100175T CY1112698T1 (el) 2005-06-27 2012-02-21 Ανοσογονος συνθεση
CY2012027C CY2012027I2 (el) 2005-06-27 2012-10-16 Μεθοδος βιομηχανικης κατασκευης εμβολιων
CY20171100234T CY1118646T1 (el) 2005-06-27 2017-02-21 Μεθοδος βιομηχανικης κατασκευης εμβολιων

Family Applications After (4)

Application Number Title Priority Date Filing Date
CY20111100883T CY1111827T1 (el) 2005-06-27 2011-09-15 Μεθοδος βιομηχανικης κατασκευης εμβολιων
CY20121100175T CY1112698T1 (el) 2005-06-27 2012-02-21 Ανοσογονος συνθεση
CY2012027C CY2012027I2 (el) 2005-06-27 2012-10-16 Μεθοδος βιομηχανικης κατασκευης εμβολιων
CY20171100234T CY1118646T1 (el) 2005-06-27 2017-02-21 Μεθοδος βιομηχανικης κατασκευης εμβολιων

Country Status (36)

Country Link
US (13) US9789179B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (11) EP1896066B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (9) JP2008543907A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (7) KR101351870B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN103083657B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2436A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (3) AR053935A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (3) ATE536884T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (7) AU2006263964B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2012C042I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (5) BRPI0612655B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (5) CA2611960C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (5) CY1109996T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE602006013313D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (7) DK1896065T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (4) EA012214B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (9) ES2901378T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR22C1008I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (4) HRP20120102T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (7) HUE031380T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (8) IL187924A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2351578T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (2) LU92085I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (4) MA29602B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (5) MX2007016405A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (3) MY148110A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300549I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (4) NO345422B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (6) NZ564371A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (6) PE20142165A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (8) PL3009146T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (8) PT2283857T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (8) SI3009146T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (5) TWI407970B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (2) UA95238C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (6) WO2007000342A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1296715T2 (sl) * 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2007000342A2 (en) * 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
EP2308504A3 (en) 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccines including serogroup C meningococcus
SI1973564T1 (sl) 2005-12-22 2017-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega konjugate kapsularnih polisaharidov Streptococcusa pneumoniae
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
PT2004225E (pt) 2006-03-22 2012-05-30 Novartis Ag Regimes para imunização com conjugados meningocócicos
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EA016417B1 (ru) 2006-09-07 2012-04-30 Глаксосмитклайн Байолоджикалс С.А. Способ получения вакцины
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US9610340B2 (en) * 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
WO2010023216A1 (en) * 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccine
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
US20120070458A1 (en) 2009-03-24 2012-03-22 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
MX2011010735A (es) 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
KR101450958B1 (ko) * 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
TWI505834B (zh) * 2009-06-22 2015-11-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
SMT201700275T1 (it) * 2009-10-30 2017-07-18 Glaxosmithkline Biologicals Sa Purificazione di saccaridi capsulari di staphylococcus aureus tipo 5 e tipo 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
JP5945538B2 (ja) 2010-08-23 2016-07-05 ワイス・エルエルシー ナイセリア・メニンギティディス（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）ｒＬＰ２０８６抗原の安定な製剤
WO2012031140A1 (en) 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
SI2809349T1 (sl) * 2012-01-30 2019-03-29 Serum Institute Of India Private Limited Imunogeni sestavek
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX2018011291A (es) 2012-03-09 2023-01-31 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
ITMI20121597A1 (it) 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
AU2013326584B2 (en) 2012-10-02 2016-12-01 Glaxosmithkline Biologicals Sa Nonlinear saccharide conjugates
KR20150100665A (ko) 2012-11-30 2015-09-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 슈도모나스 항원 및 항원 조합
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
BR112015014250A2 (pt) 2012-12-18 2017-07-11 Glaxosmithkline Biologicals Sa método para imunizar um bebê, vacina de combinação e, kit
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
DK2976101T3 (da) * 2013-03-18 2020-11-23 Glaxosmithkline Biologicals Sa Behandlingsfremgangsmåde
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
IN2014DE02450A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20220080201A (ko) * 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
WO2015158898A2 (en) * 2014-04-17 2015-10-22 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
IL303998A (en) * 2015-07-21 2023-08-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
MY199399A (en) * 2016-03-15 2023-10-25 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Novel polysaccharide-protein conjugates and process to obtain thereof
PH12019500399B1 (en) * 2016-09-02 2024-05-15 Sanofi Pasteur Inc Neisseria meningitidis vaccine
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
KR102635959B1 (ko) 2016-09-13 2024-02-14 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
CN109922828A (zh) * 2016-10-20 2019-06-21 Km生物医药股份公司 使用具有降低了的分子量的PRP的Hib结合疫苗的制造方法
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
BR112019013475A2 (pt) 2016-12-30 2020-02-27 Sutrovax, Inc. Conjugados de polipeptídeo-antígeno com aminoácidos não naturais
IL303108B2 (en) 2017-01-31 2024-07-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
KR102736151B1 (ko) 2017-09-07 2024-11-28 머크 샤프 앤드 돔 엘엘씨 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019145981A1 (en) * 2018-01-29 2019-08-01 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
US12383611B2 (en) 2019-09-27 2025-08-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4061412A1 (en) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP4243862A1 (en) 2020-11-13 2023-09-20 GlaxoSmithKline Biologicals SA Bacterial protein carriers and conjugation methods
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
WO2025021712A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
NL8500370A (nl) * 1984-02-22 1985-09-16 Sandoz Ag Diazepinoindolen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
DE58906053D1 (de) 1988-05-31 1993-12-02 Koenig Haug Beatrice Regalsystem.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
US5334379A (en) 1989-07-14 1994-08-02 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
JP2637845B2 (ja) 1989-12-14 1997-08-06 ナシヨナル・リサーチ・カウンシル・カナダ 修飾メニンゴコツクス多糖複合ワクチン
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
EP0625910B1 (en) 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ES2130265T3 (es) 1992-05-06 1999-07-01 Harvard College Region de union al receptor de la toxina difterica.
CZ283910B6 (cs) 1992-05-23 1998-07-15 Smithkline Beecham Biologicals (S.A.) Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2126616T3 (es) 1992-10-27 1999-04-01 American Cyanamid Co Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
EP0636252B1 (en) 1992-12-14 1998-03-18 I/O EXPLORATION PRODUCTS (U.S.A.), Inc. Hydraulic seismic actuator
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
DE69433341T2 (de) 1993-09-22 2004-04-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
WO1996029094A1 (en) 1995-03-22 1996-09-26 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
ES2164251T5 (es) 1995-06-07 2006-06-01 Smithkline Beecham Biologicals S.A. Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
ATE199831T1 (de) 1995-06-23 2001-04-15 Smithkline Beecham Biolog Eine impfstoffzusammensetzung,bestehend aus einem polysaccharid antigen-konjugatadsorbiert an aluminiumphosphat
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
JP4298793B2 (ja) 1996-10-23 2009-07-22 パナソニック株式会社 光ディスク
DE69739981D1 (de) 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
WO1998026799A1 (en) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU4707097A (en) 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
WO2000033882A1 (en) † 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
ES2322306T3 (es) 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
CA2689696C (en) 1999-02-26 2013-08-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
HK1043728B (en) 1999-03-19 2007-06-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
KR100833364B1 (ko) 1999-06-25 2008-05-28 와이어쓰 홀딩스 코포레이션 그람-음성 박테리아의 지질화 형태의 펩티도글리칸-결합지단백질의 생산
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
EP1233784B1 (en) 1999-12-02 2008-07-09 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stabilizing biological molecules upon lyophilization
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
SI1296715T2 (sl) 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
BRPI0112928B1 (pt) * 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
ES2388848T3 (es) * 2001-01-23 2012-10-19 Sanofi Pasteur Inc. Vacuna meningocócica polivalente preparada con un conjugado de polisacárido y proteína
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
JP2005532789A (ja) 2002-03-15 2005-11-04 ワイス・ホールデイングス・コーポレーシヨン 減少した酵素活性を有する型別不能なインフルエンザ菌（Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａ）のＰ４タンパク質の変異体
ATE419278T1 (de) * 2002-03-26 2009-01-15 Novartis Vaccines & Diagnostic Modifizierte saccharide mit verbesserter stabilität in wasser
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
MXPA04011248A (es) 2002-05-14 2005-02-17 Chiron Srl Vacunas mucosales en combinacion para la meningitis bacteriana.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
EP2258386A3 (en) 2002-08-02 2011-11-02 GlaxoSmithKline Biologicals S.A. Neisseria Vaccine composition
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
CN1401328A (zh) * 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
AR041880A1 (es) * 2002-11-01 2005-06-01 Glaxosmithkline Biolog Sa Composicion inmunogena
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
AU2004219910B2 (en) * 2003-03-13 2010-06-17 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP1624888B1 (en) * 2003-05-07 2016-10-12 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccine
PL1631264T5 (pl) 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
EP2364725A3 (en) 2003-06-23 2012-05-09 Sanofi Pasteur Inc. Immunization method against neisseria meningitidis serogroups a and c
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
CA2534870C (en) * 2003-08-06 2014-05-06 Che-Hung Robert Lee Polysaccharide-protein conjugate vaccines
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US6995363B2 (en) * 2003-08-21 2006-02-07 Applera Corporation Reduction of matrix interference for MALDI mass spectrometry analysis
PT1670506E (pt) * 2003-10-02 2013-01-28 Novartis Ag Vacinas líquidas para serogrupos meningocócicos múltiplos
ES2346314T3 (es) * 2003-10-02 2010-10-14 Glaxosmithkline Biolog Sa Antigenos de b. pertussis y uso de los mismos en vacunacion.
WO2005064021A2 (en) * 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. Vaccine
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
KR20070008625A (ko) * 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
RU2379052C2 (ru) * 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20080085289A1 (en) * 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
ES2569654T3 (es) * 2005-02-18 2016-05-12 Glaxosmithkline Biologicals Sa Proteínas y ácidos nucleicos de la meningitis / sepsis asociada a la Escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
PT1868645E (pt) 2005-04-08 2012-05-17 Wyeth Llc Composição conjugada de polissacárido-proteína pneumocócica polivalente
JP2008540398A (ja) * 2005-05-06 2008-11-20 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 髄膜炎ａ型ワクチンのための免疫原
WO2007000342A2 (en) * 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
EP2308504A3 (en) * 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccines including serogroup C meningococcus
CA2621578C (en) * 2005-09-05 2014-07-22 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
SI1973564T1 (sl) 2005-12-22 2017-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega konjugate kapsularnih polisaharidov Streptococcusa pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20080305127A1 (en) 2005-12-23 2008-12-11 Glaxosmithkline Biologicals S.A. Conjugate Vaccines
CA2644724C (en) * 2006-03-17 2016-05-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
CN103169960A (zh) * 2006-03-30 2013-06-26 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2008001224A2 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
WO2008011120A2 (en) 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
EA016417B1 (ru) * 2006-09-07 2012-04-30 Глаксосмитклайн Байолоджикалс С.А. Способ получения вакцины
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
US8885224B2 (en) * 2007-03-14 2014-11-11 Konica Minolta Business Technologies, Inc. Information embedding method, its program and information embedding device
EA201490303A1 (ru) * 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
AU2008259423A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
US9610340B2 (en) * 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2010023216A1 (en) * 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccine
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
US8974799B2 (en) * 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2545068B8 (en) * 2010-03-11 2018-03-21 GlaxoSmithKline Biologicals S.A. Immunogenic composition or vaccine against gram-negative bacterial, for example neiserial, infection or disease
JP5144836B2 (ja) 2010-06-11 2013-02-13 パナソニック株式会社 語音聴取の評価システム、その方法およびそのプログラム
JP6170932B2 (ja) * 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
GB2495341B (en) * 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
SI2809349T1 (sl) * 2012-01-30 2019-03-29 Serum Institute Of India Private Limited Imunogeni sestavek
ES2820898T3 (es) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
HRP20230359T1 (hr) * 2012-12-05 2023-06-09 Glaxosmithkline Biologicals Sa Imunogeni pripravak
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
KR20170039709A (ko) * 2014-08-05 2017-04-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원에 대한 담체 분자
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
PH12019500399B1 (en) * 2016-09-02 2024-05-15 Sanofi Pasteur Inc Neisseria meningitidis vaccine
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
IL303108B2 (en) * 2017-01-31 2024-07-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
UA128204C2 (uk) * 2017-07-18 2024-05-08 Сірем Інстітьют Оф Індіа Пвт Лтд. Імуногенна композиція з покращеною стабільністю, підвищеною імуногенністю та зниженою реактогенністю і спосіб її виготовлення

Also Published As

Publication number Publication date
NO20076343L (no) 2008-03-25
JP5769688B2 (ja) 2015-08-26
WO2007000341A2 (en) 2007-01-04
PE20110072A1 (es) 2011-02-04
BRPI0612654B1 (pt) 2021-05-04
WO2007000314A3 (en) 2007-05-31
TWI422386B (zh) 2014-01-11
MA29569B1 (fr) 2008-06-02
US20130171188A1 (en) 2013-07-04
US20090136541A1 (en) 2009-05-28
IL213718A0 (en) 2011-07-31
KR101532068B1 (ko) 2015-06-29
BRPI0612654B8 (pt) 2021-05-25
PE20070123A1 (es) 2007-02-08
ATE536884T1 (de) 2011-12-15
WO2007000342A8 (en) 2008-07-10
MX2007016237A (es) 2008-03-07
TW201336507A (zh) 2013-09-16
SI1896065T2 (sl) 2014-12-31
DK1896063T3 (da) 2012-03-19
CA2611964A1 (en) 2007-01-04
PL3009146T3 (pl) 2022-02-07
EA012214B1 (ru) 2009-08-28
MY148110A (en) 2013-02-28
NO20076363L (no) 2008-03-26
MX2007016402A (es) 2008-03-07
KR20130086087A (ko) 2013-07-30
UA95237C2 (uk) 2011-07-25
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
NO20076350L (no) 2008-03-26
CA2612957A1 (en) 2007-01-04
US20190298822A1 (en) 2019-10-03
HK1116413A1 (en) 2008-12-24
US9931397B2 (en) 2018-04-03
AR056397A1 (es) 2007-10-10
ES2901378T3 (es) 2022-03-22
US20080193476A1 (en) 2008-08-14
HK1114011A1 (en) 2008-10-24
CN103083657A (zh) 2013-05-08
SI2283857T1 (sl) 2019-11-29
HUE056842T2 (hu) 2022-03-28
MX2007016236A (es) 2008-03-07
AU2010203115A1 (en) 2010-08-12
NZ564606A (en) 2010-10-29
DK1896065T3 (da) 2011-08-29
CY2012027I1 (el) 2015-10-07
NZ564605A (en) 2011-01-28
JP2008543904A (ja) 2008-12-04
US10166287B2 (en) 2019-01-01
US20200000911A1 (en) 2020-01-02
ATE462444T1 (de) 2010-04-15
WO2007000341A3 (en) 2007-05-31
EA200702575A1 (ru) 2008-06-30
HUE031380T2 (en) 2017-07-28
DK2283857T3 (da) 2019-10-28
MY147490A (en) 2012-12-14
DE602006013313D1 (de) 2010-05-12
MA29602B1 (fr) 2008-07-01
PL1896063T3 (pl) 2012-04-30
JP5297800B2 (ja) 2013-09-25
EP1896064A2 (en) 2008-03-12
CA2611960C (en) 2015-05-05
CY1118646T1 (el) 2017-07-12
KR20080018226A (ko) 2008-02-27
BRPI0612669B8 (pt) 2021-05-25
JP2013018798A (ja) 2013-01-31
ES2741529T3 (es) 2020-02-11
IL187924A (en) 2011-11-30
IL213795A0 (en) 2011-07-31
IL188046A (en) 2012-03-29
HUE047211T2 (hu) 2020-04-28
TWI477283B (zh) 2015-03-21
EP2283857B1 (en) 2019-07-24
PL1896065T3 (pl) 2011-12-30
ATE516816T1 (de) 2011-08-15
IL188072A (en) 2017-07-31
BRPI0612670B1 (pt) 2020-04-28
HRP20170457T1 (hr) 2017-05-19
HK1116414A1 (en) 2008-12-24
US8431136B2 (en) 2013-04-30
NL300549I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-01-03
AU2006263964A1 (en) 2007-01-04
CN102526723A (zh) 2012-07-04
NZ564607A (en) 2011-06-30
US20150044253A1 (en) 2015-02-12
EP1896061B1 (en) 2019-06-12
AU2006263944B2 (en) 2012-03-01
LU92085I2 (fr) 2012-12-19
SI2878307T1 (sl) 2019-11-29
IL213795A (en) 2013-05-30
CY1111827T1 (el) 2015-10-07
NO342815B1 (no) 2018-08-13
CA2612957C (en) 2016-07-19
JP2015134829A (ja) 2015-07-27
EP2351578B1 (en) 2017-01-18
PE20142165A1 (es) 2015-01-09
US20170065714A1 (en) 2017-03-09
IL213718A (en) 2013-07-31
FR22C1008I2 (fr) 2024-01-19
EP3009146A1 (en) 2016-04-20
HRP20120102T1 (hr) 2012-02-29
AU2006263964B2 (en) 2010-05-20
CA2612980A1 (en) 2007-01-04
LU92085I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-04
TWI407970B (zh) 2013-09-11
AU2010203115C1 (en) 2013-05-02
AR056396A1 (es) 2007-10-10
BRPI0612669A2 (pt) 2010-11-30
NO344452B1 (no) 2019-12-09
NO345422B1 (no) 2021-01-25
KR101351873B1 (ko) 2014-02-17
AU2006263965A1 (en) 2007-01-04
EA200702577A1 (ru) 2008-06-30
EP3009146B1 (en) 2021-10-20
ES2377075T3 (es) 2012-03-22
AU2006263963B2 (en) 2010-05-13
SI3009146T1 (sl) 2022-02-28
NO345305B1 (no) 2020-12-07
TWI537001B (zh) 2016-06-11
ES2377075T5 (es) 2016-04-29
NZ564371A (en) 2010-05-28
EP1896061A2 (en) 2008-03-12
IL222346A (en) 2015-07-30
JP2008543905A (ja) 2008-12-04
LUC00247I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2024-10-04
US8329184B2 (en) 2012-12-11
BE2012C042I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-07-19
EP1896065A2 (en) 2008-03-12
JP5731737B2 (ja) 2015-06-10
IL188072A0 (en) 2008-03-20
FR22C1008I1 (fr) 2022-04-29
EP1896063B2 (en) 2016-03-02
TW200738259A (en) 2007-10-16
BRPI0612655A8 (pt) 2018-01-30
PT2283857T (pt) 2019-10-24
PT3009146T (pt) 2021-11-30
ES2621780T3 (es) 2017-07-05
JP5718960B2 (ja) 2015-05-13
ES2898451T3 (es) 2022-03-07
PT1896063E (pt) 2012-02-13
TW201414490A (zh) 2014-04-16
EP2201961B1 (en) 2018-01-24
DK2878307T3 (da) 2019-10-07
HRP20110567T1 (en) 2011-09-30
WO2007000322A1 (en) 2007-01-04
WO2007000343A2 (en) 2007-01-04
ES2662651T3 (es) 2018-04-09
HUS000497I2 (hu) 2021-03-29
EP1896065B1 (en) 2011-07-20
EP2201961A1 (en) 2010-06-30
HUS2200002I1 (hu) 2022-12-28
BRPI0612654A2 (pt) 2012-10-02
KR101408113B1 (ko) 2014-06-16
SI1896065T1 (sl) 2011-10-28
BRPI0612669B1 (pt) 2019-08-13
PL1896062T3 (pl) 2010-08-31
PL2351578T3 (pl) 2017-07-31
CY1112698T1 (el) 2016-02-10
EA012506B1 (ru) 2009-10-30
PL2283857T3 (pl) 2020-02-28
MA29603B1 (fr) 2008-07-01
EA200702574A1 (ru) 2008-06-30
EA013374B1 (ru) 2010-04-30
HUS1200023I1 (hu) 2021-03-29
BRPI0612656A8 (pt) 2018-01-23
CY2012027I2 (el) 2015-10-07
US20180064806A1 (en) 2018-03-08
US20090041802A1 (en) 2009-02-12
NZ590204A (en) 2012-02-24
WO2007000314A2 (en) 2007-01-04
EP2878307B1 (en) 2019-07-24
US10245317B2 (en) 2019-04-02
AU2006263936A1 (en) 2007-01-04
KR20080024222A (ko) 2008-03-17
SI2351578T1 (sl) 2017-05-31
KR101351870B1 (ko) 2014-02-17
JP2013209395A (ja) 2013-10-10
TW200730187A (en) 2007-08-16
DK1896061T3 (da) 2019-08-26
AU2006263944A1 (en) 2007-01-04
US20130004532A1 (en) 2013-01-03
AU2010212417A1 (en) 2010-09-09
CA2612963A1 (en) 2007-01-04
EP1896063B1 (en) 2011-12-14
HUE046905T2 (hu) 2020-03-30
ES2340711T3 (es) 2010-06-08
DK1896062T3 (da) 2010-06-28
EP1896066A2 (en) 2008-03-12
WO2007000343A3 (en) 2007-05-31
PE20070163A1 (es) 2007-03-01
BRPI0612656B1 (pt) 2021-09-08
HRP20110567T4 (xx) 2015-01-16
CN102526723B (zh) 2017-07-07
PE20110096A1 (es) 2011-03-07
UA95238C2 (uk) 2011-07-25
MA29993B1 (fr) 2008-12-01
SI1896063T1 (sl) 2012-03-30
JP5280199B2 (ja) 2013-09-04
KR20130122810A (ko) 2013-11-08
BRPI0612656A2 (pt) 2010-11-30
US9486515B2 (en) 2016-11-08
IL188046A0 (en) 2008-03-20
EP1896066B8 (en) 2022-01-19
EA012528B1 (ru) 2009-10-30
KR20080025184A (ko) 2008-03-19
ES2750243T3 (es) 2020-03-25
EP2878307A1 (en) 2015-06-03
KR101359953B1 (ko) 2014-02-21
PE20070499A1 (es) 2007-05-21
US9789179B2 (en) 2017-10-17
CA2611964C (en) 2016-11-08
JP5037503B2 (ja) 2012-09-26
HK1206587A1 (en) 2016-01-15
US8398983B2 (en) 2013-03-19
EP1896066B1 (en) 2021-10-27
JP5965512B2 (ja) 2016-08-03
US8883163B2 (en) 2014-11-11
AP2007004274A0 (en) 2007-12-31
CN102218138A (zh) 2011-10-19
KR20080030577A (ko) 2008-04-04
LT2351578T (lt) 2017-04-10
IL188045A0 (en) 2008-03-20
SI1896061T1 (sl) 2019-10-30
PL1896061T3 (pl) 2020-02-28
EP2351578A1 (en) 2011-08-03
AR053935A1 (es) 2007-05-23
US8846049B2 (en) 2014-09-30
US9358279B2 (en) 2016-06-07
BRPI0612670B8 (pt) 2021-05-25
WO2007000342A2 (en) 2007-01-04
JP2008543908A (ja) 2008-12-04
AU2006263963A1 (en) 2007-01-04
CA2612963C (en) 2016-10-18
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
AU2010203115B2 (en) 2012-03-15
WO2007000342A3 (en) 2007-05-31
MY147783A (en) 2013-01-31
PT1896061T (pt) 2019-08-01
BRPI0612670A2 (pt) 2010-11-30
JP2013107913A (ja) 2013-06-06
EP1896062B1 (en) 2010-03-31
WO2007000327A1 (en) 2007-01-04
EA200702576A1 (ru) 2008-06-30
PT1896065E (pt) 2011-08-31
US20100215686A1 (en) 2010-08-26
MX2007016403A (es) 2008-03-07
AU2006263936B2 (en) 2010-05-20
KR101321056B1 (ko) 2013-10-30
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
BRPI0612655A2 (pt) 2010-11-30
PL1896065T5 (pl) 2014-12-31
CA2611960A1 (en) 2007-01-04
EP1896063A1 (en) 2008-03-12
EP1896065B2 (en) 2014-09-03
US11241495B2 (en) 2022-02-08
US20080199490A1 (en) 2008-08-21
IL187924A0 (en) 2008-03-20
CN103083657B (zh) 2016-06-08
SI1896062T1 (sl) 2010-07-30
PT2878307T (pt) 2019-10-24
MX2007016405A (es) 2008-03-07
NZ564370A (en) 2011-10-28
HRP20100211T1 (hr) 2010-05-31
HUE045482T2 (hu) 2019-12-30
JP2008543907A (ja) 2008-12-04
IL214657A0 (en) 2011-09-27
JP2008543909A (ja) 2008-12-04
DK2351578T3 (en) 2017-04-24
EP1896062A1 (en) 2008-03-12
AP2436A (en) 2012-08-31
DK1896065T4 (da) 2014-10-20
ES2747025T3 (es) 2020-03-09
PT1896062E (pt) 2010-05-17
CA2612980C (en) 2019-01-15
US20090252759A1 (en) 2009-10-08
EP2283857A1 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
CY1109996T1 (el) Ανοσογονικη συνθεση
NL300903I2 (nl) Inotuzumab ozogamicin
CY1123035T1 (el) Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
AR060187A1 (es) Composicion inmunogenica
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
EP1773878A4 (en) INSULINOLIGOMER JOINTS, FORMULATIONS AND APPLICATIONS THEREOF
DK1804589T3 (da) Fedtsammensætninger
MX2009006410A (es) Conjugados de polimero-oligonucleotido, proteina y/o peptido.
CY1112682T1 (el) Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων
NO20082097L (no) Farmasoytiske sammensetninger
DK1543063T3 (da) Medikament levering
CY1112591T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
CY1115838T1 (el) Μεθοδος για τη σταθεροποιηση φαρμακοτεχνικων μορφων που περιεχουν μικροοργανισμους
DK1809661T3 (da) Humant interferon-beta-mutein
FR2884426B1 (fr) Installation pour la sterilisation d'objets par bombardement d'electrons.
WO2005003775A3 (en) Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
DE602004028236D1 (de) Pharmazeutische zusammensetzung enthaltend glucan aus mikroalgen
DK1615656T3 (da) Immunmodulerende produkt opnået ud fra en Bifidobacterium-kultur og præparater indeholdende samme
WO2007025276A3 (en) Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies
BRPI0410638A (pt) derivados de azitromicina
DK1554316T3 (da) Inklusionskompleks af en lignan
CY1106737T1 (el) Κρυσταλλικη ενωση υπο μορφη ελευθερη ή στερεου διαλυματος με αιθανολη του 4’-δεμεθυλ-4’-φωσφορικου 2’,3’-δις -πενταφθοροφαινοξυακετυλ-4’,6’-αιθυλιδενιο-β-d- γκυκοζιτη της επιποδοφυλλοτοξινης